Kyowa Kirin Co., Ltd. · TSE:4151
Kyowa Kirin — Q1 2020 Earnings Presentation
23 slides from Kyowa Kirin's earnings presentation, 2020
Slide 1: Results Presentation Fiscal 2020 First Quarter
Results Presentation Fiscal 2020 First Quarter
Slide 2: Agenda
Agenda Financial Review Motohiko Kawaguchi Executive Officer, Director of Finance Dept R&D Review Yoshifumi Torii, Ph.D Executive Officer, Vice President, Head of R&D Division Business Topics Takeyoshi Yamashita, Ph.D Executive Officer, Director of Corporate Strategy & Planning Dept Q&A © Kyowa Kiri
Slide 3: Forward-looking statements
This document contains certain forward-looking statements relating to such items as the company’s (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward-looking statements are based upon information available to the company at the present time and upon reasona
Slide 4: Financial Review
Financial Review © Kyowa Kirin Co., Ltd. 4
Slide 5: Summary of FY2020 Results
Summary of FY2020 Results ( Billion Yen / Rounded ) 2019Q1 2020Q1 2020 Changes Progress Results Results Plan Revenue 75.8 77.3 +1.5 (+2%) 327.0 24% [Overseas Ratio] [36%] [44%] [47%] Gross Profit 56.1 57.9 +1.8 (+3%) 250.0 23% [Gross Profit margin] [74%] [75%] [76%] Core OP 17.3 16.8 -0.6 (-3%) 65.0
Slide 6: YoY Analysis - Revenue
YoY Analysis -Revenue- ⚫ Japan -4.8 • Romiplate (Additional indication), G-Lasta and Rituximab BS made strong growth, however they could not cover the impact such as +1.5 billion yen the shrink of Nesp (Shift to Nesp-AG) and Patanol/Allelock (Lower pollen and COVID-19*) and NHI price-cut applied sin
Slide 7: Revenue of Major Items (Japan)
Revenue of Major Items (Japan) ( Billion yen / Rounded ) 2019Q1 2020Q1 Changes Reason 2020 Progress Item Results Results Plan Nesp + Nesp-AG* 11.8 7.4 -4.4 (-37%) 34.7 21% Nesp 11.8 1.2 -10.6 (-90%) Nesp-AG launched in Aug 2019 4.0 29% Nesp-AG ー 6.3 +6.3 30.7 20% Regpara 1.8 1.0 -0.9 (-48%) Switch t
Slide 8: Revenue of Major Items (Overseas)
Revenue of Major Items (Overseas) ( Billion yen / Rounded ) 2019Q1 2020Q1 Changes Reason 2020 Progress Item Results Results Plan Crysvita*1 5.7 12.0 +6.3 (+110%) Steady market penetration 56.6 21% North America 9.2 EMEA 2.8 Poteligeo 2.4 2.9 +0.5 (+22%) Launched in Oct 2018 14.3 20% Nourianz － 0.4 +
Slide 9: YoY Analysis - Core OP
YoY Analysis -Core OP- -0.6 billion yen ⚫ Gross Profit +1.8 (incl. forex effect -0.1) • Increased in conjunction with the rise in revenue. (incl. forex effect -0.1) Gross profit margin up by 1 point, from 74% to 75%. (¥Bn) ⚫ SG&A -3.0 (incl. forex effect +0.1) • Increased selling and launch readines
Slide 10: YoY Analysis - Profit
YoY Analysis -Profit- Profit (Jan-Mar) +5.7 billion yen (¥Bn) • KHB shares sold in Apr 2019 (19Q1 result of Bio-Chemicals business -1.2) • Business restructuring expenses (5.1→1.6) +3.5 Core Operating Profit -0.6 Profit from Continued Operation +4.5 © Kyowa Kirin Co., Ltd. 10
Slide 11: R&D Review
R&D Review © Kyowa Kirin Co., Ltd. 11
Slide 12: Key Development Updates in 20Q1
Key Development Updates in 20Q1 • Acceptance of marketing authorization application for approval of KW-6002 for Parkinson’s disease1 in Europe (January) • Application for marketing authorization of KHK4827 for axial spondyloarthritis and psoriatic arthritis in Taiwan (February) • Initiation of the p
Slide 13: Business Topics
Business Topics © Kyowa Kirin Co., Ltd. 13
Slide 14: Business Topics after April
Business Topics after April • A Global partnership with MEI Pharma on Global license, Development, and Commercialization for ME-401（April） • Impacts of COVID-19 • No impact has been reported regarding procurement and the product supply. • In order to take required actions in a timely manner, we will
Slide 15: Appendix
Appendix © Kyowa Kirin Co., Ltd. 15
Slide 16: FOREX Information
FOREX Information Average FOREX Rate (Yen) 2019Q1 2020Q1 2020 Currency Changes Results Results Plan USD/JPY 110 110 － 105 GBP/JPY 143 143 － 130 2020Q1 FOREX Impact (YoY) (Billion yen) Currency Revenue Core OP USD/JPY － － GBP/JPY － － FY2020 Currency Fluctuation Sensitivity (Billion yen) Currency Chan
Slide 17: Key progress in development (2020 Q1)
Key progress in development (2020 Q1) Note: Listed events were completed between January 1st, 2020 and March 31st, 2020. Generic name Month Code Indication Country/region Event Istradefylline Jan. KW-6002 Parkinson’s disease EU Accepted MAA Pegfilgrastim Feb. KRN125 Chemotherapy induced febrile neut
Slide 18: Submission plan of major pipeline
Submission plan of major pipeline As of March 31st, 2020 Generic name Code Indication Country/region 2020 H1 2020 H2 2021 Brodalumab KHK4827 Psoriasis CN + Brodalumab KHK4827 Psoriasis AS + + Brodalumab KHK4827 Axial spondyloarthritis JP + Brodalumab Axial spondyloarthritis KHK4827 Psoriatic arthrit
Slide 19: Development plan of major pipeline
Development plan of major pipeline As of March 31st, 2020 Generic name Code Indication Country/region 2020 2021 2022~ Bardoxolone methyl Diabetic Kidney disease RTA 402 JP Phase 3 Bleselumab1 Recurrence of FSGS in de ASKP1240 novo kidney transplant US Phase 2 Phase 3 Entinostat Breast cancer KHK2375
Slide 20: Estimated annual incidence/prevalence
Estimated annual incidence/prevalence Disease Country Estimated # of Incidence (i) Source /Region or Prevalence (p) ATL Japan i: 1,150 per year i: Survey and countermeasures to HTLV-1 infection and related diseases in Japan. 2009 summary p: 2,000 research report (Yamaguchi, 2010) p: Ministry of Heal
Slide 21: Crysvita - Collaboration with Ultragenyx
Crysvita ‐ Collaboration with Ultragenyx ‐ Kyowa Kirin Group Ultragenyx ⚫ Books sales ⚫ For first 5 years, splits profits in half U.S.A ⚫ For first 5 years, splits profits in half ⚫ After 5 years, receives mid to high 20% range sales /Canada ⚫ After 5 years, pays mid to high 20% range sales royalty
Slide 22: List of acronyms
List of acronyms AA Aplastic Anemia AD Atopic Dermatitis ATL Adult T-Cell Leukemia/Lymphoma BS Biosimilar CKD Chronic Kidney Disease CTCL Cutaneous T-Cell Lymphoma DKD Diabetic Kidney Disease ENS Epidermal Nevus Syndrome FSGS Focal Segmental Glomerulosclerosis HAM HTLV-1 Associated Myelopathy HSC He
Slide 23: Kyowa Kirin Co., Ltd. Corporate Communications Dept., IR Group
Kyowa Kirin Co., Ltd. Corporate Communications Dept., IR Group +81-3-5205-7206 / ir@kyowakirin.com